Generic Name and Formulations:
Avatrombopag 20mg; tabs.
RECENT UPDATESMonograph added.
Indications for DOPTELET:
Thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Start treatment 10–13 days prior to procedure; undergo procedure within 5–8 days after last dose. Take with food. Platelet count <40 x 109/L: 60mg once daily for 5 days; 40–<50 x 109/L: 40mg once daily for 5 days.
Obtain platelet count prior to treatment and on day of procedure. Increased thrombotic risk with known risk factors (eg, Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency, Protein C or S deficiency). Do not use to normalize platelet counts. Pregnancy; may cause fetal harm. Nursing mothers: not recommended (during and for ≥2 weeks after last dose).
Thrombopoietin receptor agonist.
Pyrexia, abdominal pain, nausea, headache, fatigue, peripheral edema; thrombotic/thromboembolic complications.
Neurology Advisor Articles
- Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults
- Epilepsy's Mobility Problem: Advocating for Changes in Transportation Laws, Public Resources
- The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
- Women With Epilepsy More Likely to Have Major Depressive Disorder
- Some Common Allergies Linked to Odds of Autism in Children
- CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy
- Long-Term Type 1 Diabetes Associated With Cognitive Decline
- White Matter Hyperintensities in RCVS Vary Over Time
- Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease
- Levetiracetam Effective as Episodic Migraine Prophylactic